INTRODUCTION {#S1}
============

Obesity is a common disorder with both environmental and genetic determinants ([@R1]). Its frequency has now reached epidemic proportions with the number of affected individuals in the United States approaching 100 million ([@R2]). The Metabolic Syndrome (MetS) is a form of obesity characterized by a cluster of phenotypes that include enlargement of the abdominal/visceral fat compartment, insulin resistance and glucose intolerance, dyslipidemia with increased plasma levels of triglycerides and decreased levels of HDL-cholesterol, increased blood pressure, and elevated circulating cytokines and adipokines. It is associated with increased risk for type 2 diabetes and cardiovascular disease ([@R3]).

Twin, familial and population studies have confirmed existence of a genetic basis for MetS ([@R4]). Several studies have identified a number of candidate and/or animal homology genes that are associated with its phenotypic expression ([@R5], [@R6]). Recent studies have employed genome-wide association scans (GWAS) and genome-wide expression profiling ([@R7], [@R8], [@R9],[@R10]). However, these discoveries account for only a small percentage of the total variance of the MetS traits, and the full spectrum of contributing loci is likely to be larger.

We previously performed a genome-wide linkage scan using microsatellite markers at 10 centiMorgan (cM) intervals in 2,209 members of 507 nuclear families of predominantly Northern European ancestry ([@R11]). Quantitative trait linkage analysis revealed a highly significant locus (QTL) at chr3q27 associated with body composition and insulin/glucose responsiveness. A second locus was linked to plasma leptin levels at chr17p12. Plasma levels of leptin, an adipose tissue product, have been found correlated with total body adiposity. These findings were replicated in several studies of different ethnic groups ([@R12], [@R13]). These QTLs were also found to be epistatically interactive and pleiotropic, influencing a broad spectrum of the MetS phenotypes ([@R11]).

The present study was undertaken in 1,137 individuals in 352 nuclear families (85 extended families) of Northern European descent from the cohort that contributed to the QTL linkage. We conducted an in-depth phenotyping procedure by measuring 42 MetS traits that included both clinical outcome and biologic precursor phenotypes. In addition, we obtained dense haplotype-tagging SNP genotypes and transcriptional profiles of peripheral blood mononuclear cells (PBMCs) for a subset of these individuals. Gene prioritization was based upon biologic relevance as well as SNP and PBMC expression associations with the MetS phenotypes.

METHODS AND PROCEDURES {#S2}
======================

Subjects and phenotypes {#S3}
-----------------------

The study cohort consists of 1,137 individuals representing 85 extended nuclear families. Analysis of distribution of pairwise relationships showed the majority of the number of pairs were highest of parent-offspring (n=1300) and between siblings (n=1494). Details of recruitment and phenotyping procedures have been described previously ([@R11]). Briefly, each family was recruited through an obese proband (BMI ≥ 30) with the minimal requirement of the availability of one obese sibling and one never-obese (BMI ≤ 27) and availability of at least one, preferably both, of the parents. Clinical phenotypes included weight, height, BMI, waist circumference (WC), hip circumference (HC), waist to hip ratio (WHR), fasting glucose (FG), fasting insulin (FI), insulin to glucose ratio (IGR), homeostasis model assessment (HOMA), plasma triglycerides (TG), total cholesterol (TC), LDL-cholesterol (LDL-c) and calculated LDL-cholesterol levels (cal. LDL-c), HDL-cholesterol (HDL-c), systolic and diastolic blood pressure (sBP and dBP) and pulse. Biological phenotypes were determined according to standard published procedures, included measurement of total fat mass in kilogram and percentage (Fatkg and Fatpct) and lean mass in kilogram and percentage (Leankg and Leanpct) by Dual-emission X-ray absorptiometry (DEXA) ([@R14]); total abdominal, visceral and subcutaneous fat sizes (TAF, VF and SubQF) by computed tomography (CT/MRI) scans average of three sections at the fourth lumbar spine ([@R15]); resting energy expenditure (REE) and respiratory quotient (RQ) were measured in resting subjects using a Deltatrac Indirect Calorimeter (Sensor Medics, VIASYS Healthcare, Conshohocken,PA) after a 10 hr fast; insulin/glucose responsiveness indices: insulin sensitivity (SI), glucose effectiveness (SG), acute insulin response to glucose (AIR~G~) and disposition index (DI) by Minimal Model ([@R16]); lipids/lipoprotein sizing \[HDL median diameter (HMED), LDL-cholesterol median diameter (LMEDn), LDL-cholesterol dominant peak diameter (LDLppd) and apoB-containing non-HDL median diameter (BMED) which includes VLDL, ILDL, LPα and LDL\] were measured by polyacrylamide gradient gel electrophoresis ([@R17]); circulating levels of adiponectin, leptin by a double antibody, equilibrium RIA (Millipore Corporation, Billerica, MA); and TNF-alpha, interleukin-1beta (IL-1β) and interleukin-6 (IL-6)\] as described ([@R18]). All study procedures for adults and children were approved by the Institutional Review Boards of the Medical College of Wisconsin and Children's Hospital of Wisconsin, respectively.

SNP Genotyping and Data Cleaning {#S4}
--------------------------------

Genomic DNA was extracted and prepared from whole blood using commercial kits (Puregene, Minneapolis, MN). Genome-wide SNP genotyping was performed using Affymetrix Genome-Wide Human SNP 6.0 arrays and SNP calls were generated by Genotype Console 3.2. Individuals with fewer than 95% of available markers called were excluded. 869,222 autosomal SNPs were prepared by Preswalk and checked for Mendelian consistency with SimWalk2. A SNP was eliminated if: 1) fewer than 95% of the cohort were typed successfully; 2) the SNP was monoallelic; 3) the SNP had more than two alleles; 4) fewer than five copies of the SNP existed in the study cohort. Hardy-Weinberg equilibrium (HWE) was tested for each SNP using SOLAR ([@R19]); SNPs with excessive deviation from HWE (p \< 10^−8^) were excluded. Missing SNP data were imputed with MERLIN ([@R20]).

Transcriptional profiling {#S5}
-------------------------

Genome-wide transcriptional profiles of a subset of the SNP genotyping cohort (369 individuals from 55 nuclear families) were obtained as previously described ([@R21]) with modifications. Briefly, for each individual 2.5ml blood was collected into a PAXgene® Blood RNA Tube (BD, Franklin Lakes, NJ) following an overnight fast. Total RNA was isolated from each tube using the PAXgene Blood RNA Kit (Qiagen, Valencia, CA) and anti-sense RNA (aRNA) was synthesized using the MessageAmp II-Biotin aRNA kit (Ambion, Austin, TX). A total of 1.5 μg aRNA was hybridized to Illumina HumanWG-6 version 2 or version 3 chips (Illumina, San Diego, CA) and expression detected on the Illumina® BeadArray™ 500GX Reader. Illumina GenomeStudio software (version 2010.3) was used for preliminary data analysis with standard background normalization.

Statistical Analysis {#S6}
--------------------

### Variance-component-based pedigree analysis {#S7}

The heritability of each of the 42 MetS traits was first established, then a bivariate analysis in SOLAR was used to partition phenotypic correlations between the traits into presumed environmental and additive genetic components, as described previously ([@R22]).

### Measured genotype analysis {#S8}

In SOLAR, each SNP genotype was converted to a covariate measure equal to 0, 1 or 2 copies of the minor allele (or, for missing genotypes, a weighted covariate based on imputation). These covariates were included in variance-components mixed models for measured genotype analyses ([@R23]) versus null models that incorporated the random effect of kinship and fixed effects such as age, age^2^, sex and their interactions. Individual scores from a principal components analysis of representative SNPs were also included to correct for possible population stratification ([@R24]).

Within chromosomal regions showing the strongest prior evidence of linkage (as logarithm of odds, LOD, score) with MetS traits in our MRC-OB cohort, we selected all available SNPs on the Affymetrics 6.0 array that mapped within a 1-LOD confidence interval of the maximum LOD score in each region. Each SNP covariate was tested independently in a 1 degree of freedom likelihood ratio test. To account for the linkage disequilibrium between SNPs, we calculated the effective number of independent SNPs (N~eff~) using the method of Moskvina & Schmidt ([@R25]). Critical p-values were calculated using Bonferroni/Šidák correction for each linkage region based on its N~eff~.

### Gene expression analysis {#S9}

Microarray data were available in two batches, one of Version 2 arrays (48,701 probes, 307 samples) and the other of Version 3 (48,803 probes, 230 samples). To guard against possible batch effects and probe differences, each batch was analyzed separately: The number of probe transcripts detectable at p≤0.05 by BeadStudio software was counted, a false discovery rate (FDR) was computed across all probes, and transcripts detectable at 5% FDR were retained. Expression levels were log~2~ transformed and inverse-quartile normalized. Transformed and normalized expression levels for probes that mapped to the 1-LOD QTL regions were tested for association with each phenotype in models that included the random effect of kinship. Gene-centric p-values were calculated by combining independent p-values from the two microarray batches and multiple probes using Stouffer's weighted Z-score method ([@R26]) implemented in R.

RESULTS {#S10}
=======

Heritability and genetic inter-correlation {#S11}
------------------------------------------

A total of 1,137 individuals, representing extended families that contributed to the linkage on chromosomes 3 and 17 ([@R11]), were recruited and measured for the clinical phenotypes. 503 of those also underwent the biologic phenotyping procedures and 369 individuals also provided blood PBMCs for the transcriptional profiling. Their mean (±SD) age was 40.29y±SD=17.68y and ranged from 6 to 90y, 11.7% of the subjects were younger than age 18 and 58.3% of the subjects were female. [Table 1](#T1){ref-type="table"} shows means (± SD) of the 42 phenotypes and their levels of heritability. All phenotypes measured were significantly heritable (p \< 0.05), justifying further genetic analysis.

[Figure 1](#F1){ref-type="fig"} illustrates the traits that significantly inter-correlated genetically. BMI, the trait most commonly used in GWA analyses as the phenotype representing the degree of obesity, was correlated with the other phenotypes of body composition (WC and HC), insulin responsiveness (FI, IGR and HOMA), and lipid panel (TG and HDL-c). BMI was also significantly correlated with both total body fat and lean masses (Fatkg, Fatpct, Leankg and Leanpct. WC, another commonly used phenotype to represent central body or visceral fat distribution, was significantly correlated with clinical phenotypes of insulin responsiveness (IGR and HOMA), plasma lipids (TG and HDL-c) and cardiovascular performance measures (resting pulse and sBP). As with BMI, it was correlated both with visceral and subcutaneous fat masses (VF and SubQF). WHR, another clinical phenotype of body fat distribution, on the other hand was correlated with VF, REE, lipoprotein density profile and circulating levels of TNF-alpha. Of the biologic phenotypes, Fatkg was genetically correlated with REE, phenotypes of insulin responsiveness (SI, SG and AIR~G~), LDL peak size (LDLppd), and plasma leptin. VF was also genetically correlated with measures of body composition, REE, insulin sensitivity (SI), and plasma of IL-6. AIR~G~ was correlated with Leankg, insulin responsiveness (DI), and leptin. Finally, SI, a direct marker of insulin sensitivity, was genetically correlated with all biologic measures of body composition (Fatkg, Leankg, Fatpct and Leanpct) and clinical parameters of insulin response.

SNP genotype-phenotype association {#S12}
----------------------------------

[Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} show the highest levels of association of SNPs bordered by 1 LOD score drop from the linkage peak at 3q27 QTL (LOD~BMI~=3.3) and 17p12 (LOD~Leptin~=5.0), respectively. The strength of the association is indicated by the negative logarithm of p-values. The genes representative of this association annotated from those SNPs (hg18/NCBI36 human genome assembly) are also shown. The regional threshold for associations was determined by Bonferroni/Šidák correction for the effective number of independent SNPs given their linkage disequilibrium (n~SNPs~=6305, n~effective~=3881.47, p~α=0.05~=1.32×10^−5^, 3q27; n~SNPs~=1629, n~effective~=1412.93, p~α=0.05~=3.63×10^−5^, 17p12) ([@R28]).

QTL3q27 {#S13}
-------

### Body composition and insulin responsiveness {#S14}

[Table 2](#T2){ref-type="table"} shows four biologically relevant genes identified in this region to be associated with body composition and insulin/glucose responsiveness. Transducing (beta)-like 1 X-linked receptor 1 (*TBL1XR1*) (rs6443434 and rs11710431), a signal transducer influencing multiple biological functions including cytoskeletal assembly, was associated with both clinical (weight and BMI) and biologic (Leanpct, REE, TAF and SG) traits. Insulin-like growth factor 2 mRNA-binding protein 2 (*IGF2BP2*) (rs12639517), known to regulate *IGF2* mRNA translation, was associated with the identifier phenotype WHR. Neuroligin 1 (*NLGN1*) (rs569221), a brain synapses protein, was associated with Leankg. Lipoma-preferred partner (*LPP*) (rs6785028), a cell adhesion and growth signal communicator, was associated with AIR~G~. Within this region, there were two associations that exceeded the regional significance threshold. SNP rs7433602 mapped to N-acetylated alpha-linked acidic dipeptidase-like 2 (*NAALADL2*), a dipeptidase that lacks a functional domain, was associated with VF. SNP rs10933727 was associated with HOMA and was mapped to a hypothetical gene *LOC100131551*.

### Lipids/lipoprotein and cardiovascular performance {#S15}

Of the lipids/lipoprotein phenotypes, there are two biologically relevant genes disclosed by SNP association. *ATP11B* (rs2700839) in association with LDLppd is an ATPase functioning in ion transport in cell membrane. Another gene, Rho family guanine nucleotide exchange factor (*MCF2L2*), referred by rs7631640 was associated with pulse. It was identified as a gene associated with type 2 diabetes ([@R27]). Only one association in this category was above the regional significance threshold, that is, rs10937009 with BMED. This SNP is near the gene NADH dehydrogenase (ubiquinone) 1 beta (*NDUFB5*), which transfers electrons from NADH to the respiratory chain.

### Adipokine/cytokines {#S16}

In the adipokine/cytokines phenotype category, we identified a biologically relevant association between rs6807480 and circulating IL-6 that is annotated to gene *FGF12*, a fibroblast growth factor. Another association above the threshold was between rs13070418 and TNF-alpha. This SNP was annotated to the gene *SOX2*, a transcription factor functioning in embryonic development.

QTL17p12 {#S17}
--------

### Body composition and insulin responsiveness {#S18}

There are seven biologically relevant genes annotated to SNP-phenotype associations ([Table 3](#T3){ref-type="table"}). Three of those were identified by multiple associations, including *TNFRSF13B* (eight associations), *HS3ST3A1* (eight associations) and *MYOCD* (four associations). Of those, *TNFRSF13B*, a pro-inflammtory macrophage receptor, was associated with VF and TAF at levels above regional significance threshold. *HS3ST3A1* \[heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1\], a heperan sulfate biosynthesis enzyme, was associated with HC, DEXA measures of body fatness and leanness, and several of the other biological phenotypes which index insulin responsiveness (SG and AIR~G~). *MYOCD* (myocardin), a cardiogenesis regulator, was associated with clinical phenotypes of body weight, BMI and WC. There were four associations annotated to potentially important biological regulator genes relevant to MetS. *RICH2*, a Rho-GTPase activator, was associated with Fatpct. *TRPV2* (transient receptor potential cation channel), a heat responsive channel, was associated with RQ. *COX10* (cytochrome c oxidase component 10), an essential component of the mitochondrial respiratory chain, was associated with FG. *PMP22* (peripheral myelin protein 22) associated with SI, is known to function in the peripheral nervous system.

### Lipids/lipoprotein and cardiovascular performance {#S19}

Five of the body composition associated genes were also associated with phenotypes in this category. *RICH2* was associated with TG. *MYOCD* was associated with TC. *HS3ST3B1*, a sister to *HS3ST3A1*, was associated with LDL-c. *PMP22* was associated with HMED (above the threshold). *TNFRSF13B* was associated with sBP. Finally *MPRIP*, which is a myosin phosphatase Rho interacting protein, was associated with three of the lipoprotein sizing measures (LMEDn, LDLppd and BMED).

### Adipokine/cytokines {#S20}

Associations with adiponectin and TNF-alpha were mapped to *HS3ST3A1*, which was also associated with body composition and insulin responsiveness. *COPS3* (COP9 constitutive photomorphogenic homolog subunit 3), a kinase regulating signal transduction, was associated with IL-6.

### PBMC mRNA expression {#S21}

Of the biologically relevant genes identified by SNP association at 3q27 and 17p12, [Tables 4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} show the association (as in p-values) of transcript levels in relation to each of the 42 phenotypes. At 3q27, expression of three biologically relevant genes, *LPP*, *IGF2BP2* and *TBL1XR1*, were strongly associated with (p\<0.01) MetS phenotypes. *ATP11B*, *MCF2L2*, and *NLGN1* had nominal associations with MetS phenotypes (p\<0.05). *LPP* was found associated with both biologic and clinical phenotypes (REE/weight, IL-1β, FI, TG, and HDL-c). *IGF2BP2* was associated with body weight, BMI, WC, HC, Fatkg, Fatpct, Leankg and Leanpct, RQ, REE, SI, DI, LDL-c, HMED, LDLppd and leptin. *TBL1XR1* was associated with Leankg and resting pulse. *ATP11B* was associated with WHR, *MCF2L2* with SI, LDLppd and BMED, and *NLGN1* with FG. Of the seven genes identified by SNP-phenotype association as biological relevant, the transcript levels of only one gene, *FGF12*, did not pass any significant level. At 17p12, of the eight biologically relevant genes, seven had transcription levels significantly associated with related MetS phenotypes: *TNFRSF13B*, *COX10*, *RICH2*, *TRPV2, MPRIP*, *COPS3* and *PMP22*. *TNFRSF13B* was associated with WHR, RQ, LDLppd and BMED. *COX10* was associated with weight, BMI, SG and TG. *PMP22* was associated with TG and HMED, and *RICH2* with Leankg, REE, AIR~G~ and leptin. *TRPV2* was associated with fat mass, lean mass and REE/leanmass, and *MPRIP* with TG, HMED and pulse. *HS3ST3B1* was not represented in our transcriptomic profile. However, because of its extensive SNP association with multiple biologic phenotypes, and because of its known relevant function, we prioritized it as a significant candidate.

### Summary of candidate gene prioritization {#S22}

[Table 6](#T6){ref-type="table"} summarizes the prioritized genes identified by SNP association in the two QTL regions, their identifier phenotype and the genetic correlates of this identifier. The steps of this prioritizing strategy included the level of significance of the SNP associations, function of identified gene in relation to the MetS and level of PBMC gene expression in association with the MetS phenotypes. [Figure 2A and 2B](#F2){ref-type="fig"} show the final four prioritized genes located within the QTL peaks at 3q27 and 17p12, together with their identifier phenotype(s).

Discussion {#S23}
==========

The present study focused on identification of genes situated in previously-determined QTLs at chr3q27 and chr17p12. Both targeted SNP genotype association and mRNA expression analyses were performed. The results provided for the first time clarification of the differential informativeness of the clinical phenotypes vs. concomitantly measured biologic traits. Although BMI and waist circumferences, the commonly used phenotypes in the GWAS meta-analyses, were genetically intercorrelated with other clinical phenotypes of MetS, they were not reflecting their biologically targeted traits. BMI was intercorrelated with both total body fat and lean mass. Waist circumferences were also intercorrelated with subcutaneous and visceral fat sizes. Within each of the QTLs a number of genes were found to be associated with the multiple phenotypes of body composition, insulin responsiveness, lipoprotein density profiles and cytokines. Our results revealed two novel genes (*IGF2BP2 and TNFRSF13B*), whose function could account for the biologic pathways influencing MetS phenotypes. *IGF2BP2* is also known to mediate glucose/insulin response effectiveness. *TNFRSF13B* is a mediator of cytokine activities like TNF-alpha and its influence on the pro-inflammatory response. Our results thus unraveled the genetic origin of the epistatic and pleiotropic effects exerted by the identified QTLs with their potential influences on MetS. It also emphasizes the rationale behind the extensive efforts and the cost encountered in measuring the biologic phenotypes in order to identify those genes participating in the evolution of MetS phenotypic clusters.

To prioritize genes mapped to the associated SNPs, we stressed their biologic function, statistical level and association of selected genes' expression levels with related MetS phenotypes. In this respect, our highest level of priority at 3q27 was *IGF2BP2* whose sequence polymorphism was associated with WHR, the only clinical phenotype that was genetically intercorrelated with visceral fat size (VF). WHR was also correlated with other biologic markers including REE, all lipoprotein sizes profile and cytokine TNF-alpha. The transcript levels of *IGF2BP2* were also significantly associated with biologic measures of body composition phenotypes (Fatkg, Leankg, RQ and REE), insulin/glucose responsiveness (SI and DI), lipoprotein sizes profile (HMED and LDLppd) and plasma leptin. The protein product of *IGF2BP2* binds the mRNA of insulin-like growth factor 2 (IGF2) and therefore regulates its translation. IGF2 is a hormone that affects growth and development in neonatal stages ([@R28]). In adults, IGF2 is known to influence regulation of lipids/lipoprotein metabolism and body weight ([@R29]). Lean type 2 diabetic men and women whose weight gain within the next five years can be predicted by circulating levels of IGF2 ([@R30]). In a number of genome-wide association studies, *IGF2BP2* has also been found to be associated with the onset of type 2 diabetes ([@R31], [@R32]).

At 17p12 QTL, our first priority gene is *TNFRSF13B*, a member of a well-characterized receptor family for tumor necrosis factors. Polymorphisms in the proximity of *TNFRSF13B* were associated with four MetS phenotypes. High levels of associations were observed for multiple variants near or within *TNFRSF13B* with VF and TAF, two of the most informative biological phenotypes of body fat distribution. Plasma leptin levels, the identifier phenotype of this linkage region has been recognized to be a surrogate of adverse adiposity between VF and SubQF ([@R33]). In our cohort leptin levels were genetically correlated with SubQF and TAF. We also observed association of the transcript levels of *TNFRSF13B* with WHR, RQ, LDLppd and BMED. TNFRSF13B, sometimes referred to as TACI (transmembrane activator) or CAML (calcium-modulating cyclophilin ligand interactor), is a receptor shared by two members of the tumor necrosis factor superfamily, APRIL (TNFSF13) and BAFF (the B-cell activation factor of the TNF family). APRIL and BAFF can activate macrophages via shared receptors such as TACI and initiate inflammatory changes leading to the induction of mediators of pro-inflammatory cytokines and matrix degrading enzymes ([@R34], [@R35]). Adverse adiposity distribution particularly accumulation of visceral fat mass is linked to insulin resistance. One possible hypothesis is that chronic state of inflammation largely attributed to macrophage infiltration of visceral adipose tissue could play a major causative role in the pathogenesis of MetS. Our results suggest a role for *TNSRSF13B* in the etiology of several phenotypes that may be genetically linked via a network through inflammatory pathways. These include VF, TAF, REE, WHR, and some lipid densities subclasses.

Based on our filtering criteria focusing on the biology of MetS, our other prioritized genes include *LPP*, *MCF2L2*, *TBL1XR1*, *ATPB11* and *NLG1* at 3q27 and *HS3ST3A1, COX10*, *PMP22*, *RICH2*, *TRPV2* at 17p12. Some of these genes have been implicated in functions that may potentially be related to the pathogenesis of MetS but more research is needed to elucidate their precise biological role. We also noticed that none of the SNPs we found significantly associated with MetS traits in our cohort have been identified in previous GWAS for related phenotypes. The genes some of these SNPs are mapped to, including *IGF2BP2* and *TNFRSF13B* ([@R31], [@R32], [@R36]), have been implicated in diabetes related phenotypes. In conclusion, our QTL-based association and PBMC expression genetic analyses guided by biology-focused approach revealed novel genes that could account for the complexity of MetS phenotypes both in relation to their informativeness as well as the epistatic and pleiotropic influences of its identified QTLs. They also account at least in part for potential biologic pathways underlying the MetS phenotypes. Whereas *IGF2BP2* could relate to aberrations in glucose/insulin responsiveness, *TNFRSF13B* could mediate its association with adverse adiposity as well as aberrations of plasma lipids/lipoprotein sizes profile.

Dr. Ahmed Kissebah, the senior author of this work, was fully involved in the preparation of this report up to his death on 17 May 2012. We are saddened by his loss and deeply respectful of his long and distinguished career in obesity research.
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![Genetic inter-correlation between MetS phenotypes\
Heat map of pairwise genetic intercorrelation of 42 phenotypes. Colored tones represent only significant (p\<0.05) correlations, red the strongest and yellow the weakest. A genetic correlation significantly different from zero suggests that the trait pair is influenced by the same gene or by genes in linkage disequilibrium. For abbreviations and units, see [Table 1](#T1){ref-type="table"}.](nihms-434076-f0001){#F1}

![Plots of SNP associations with MetS phenotypes within QTLs at 3q27 (panel A) and 17p12 (panel B)\
Dots depict levels of association of identifier phenotypes with all SNPs in the QTL region. Vertical axis represents minus logarithm of the p-values and horizontal represents the chromosomal position (kb). In panel A, *LPP* and *IGF2BP2* are the highly prioritized genes in the 3q27 QTL region. In panel B, *TNFRSF13B* and *HS3ST3A1* are the highly prioritized genes in the 17p12 QTL region.](nihms-434076-f0002){#F2}

###### MetS Cohort phenotypic characteristics and heritability levels.

[Table 1](#T1){ref-type="table"} shows mean (±SD) and additive heritability of 42 clinical and biologic phenotypes of MetS. For cohort recruitment and phenotyping, see Methods. Clinical phenotypes were measured in 1,137 individuals from 85 extended families that contributed highly to the linkages at 3q27 and 17p12 loci. Biologic phenotypes were measured in 503 individuals.

  ----------------------------------------------------------------------------------------------------------------------------
                                                              Trait                        Mean            Heritability ± SE
  ----------------------------------------------------------- ---------------------------- --------------- -------------------
  **Body composition and insulin responsiveness**             Weight, kg                   87.57 ± 27.36   0.47 ± 0.06

  Height, cm                                                  167.7 ± 12.45                0.56 ± 0.05     

  BMI, kg/m~2~                                                30.94 ± 9.31                 0.44 ± 0.06     

  Waist circumference (WC), cm                                95.56 ± 21                   0.40 ± 0.06     

  Hip circumference (HC), cm                                  107.94 ± 22.04               0.57 ± 0.05     

  Waist to Hip ratio (WHR)                                    0.89 ± 0.1                   0.31 ± 0.06     

  Total Fat Mass (Fatkg), kg                                  32.36 ± 16.47                0.50 ± 0.1      

  Total Fat Mass (Fatpct),%                                   36.61 ± 12.14                0.48 ± 0.1      

  Total Lean Mass (Leankg), kg                                51.87 ± 13.56                0.66 ± 0.09     

  Total Lean Mass (Leanpct), %                                65.58 ± 31.75                0.44 ± 0.1      

  Subcutaneous Fat (SubQF), g                                 311.9 ± 176.7                0.57 ± 0.1      

  Visceral Fat (VF), g                                        177.9 ± 111.3                0.32 ± 0.07     

  Total Abdominal Fat (TAF), g                                489.8 ± 248.8                0.51 ± 0.1      

  Respiratory Quotient (RQ)                                   0.83 ± 0.08                  0.35 ± 0.09     

  Resting Energy Expenditure (REE), kcal/24 hrs               1740.5 ± 342.21              0.31 ± 0.09     

  REE/weight, kcal/24hrs/kg                                   19.26 ± 3.47                 0.32 ± 0.11     

  REE/Lean mass (REE/LM), kcal/24hrs/kg                       33.48 ± 6.18                 0.36 ± 0.1      

  Fasting Glucose (FG), mmol/l                                4.86 ± 1.64                  0.38 ± 0.05     

  Fasting Insulin (FI),pmol/l                                 107.5 ± 105.6                0.30 ± 0.05     

  Insulin/glucose (IGR)                                       0.25 ± 0.62                  0.25 ± 0.05     

  Homeostasis model assessment (HOMA)                         4.31 ± 8.5                   0.30 ± 0.05     

  Insulin Sensitivity (SI), (× 10^−4^/min/μU/ml)              3.05 ± 2.83                  0.15 ± 0.09     

  Glucose Effectiveness (SG), min^−1^                         0.02 ± 0.01                  0.13 ± 0.08     

  Acute Insulin Response to glucose (AIR~G~), μU/ml × 10min   467.02 ± 400.51              0.52 ± 0.08     

  Disposition Index (DI), AUC (Insulin~0-10\ min~) × SI       1191.18 ± 1081.76            0.26 ± 0.09     

                                                                                                           

  **Lipids/lipoprotein profiles**\                            Triglycerides (TG), mmol/l   1.33 ± 1.29     0.38 ± 0.06
  **and cardiovascular**\                                                                                  
  **performanc**                                                                                           

  Total Cholesterol (TC), mmol/l                              4.88 ± 1.16                  0.34 ± 0.05     

  LDL-cholesterol (LDL-c), mmol/l                             3.19 ± 0.98                  0.28 ± 0.05     

  Calculated LDL-C (cal. LDL-c), mmol/l                       3.25 ± 1.16                  0.35 ± 0.05     

  HDL-cholesterol (HDL-c), mmol/l                             1.06 ± 0.37                  0.64 ± 0.06     

  HMED, nm                                                    8.93 ± 0.55                  0.53 ± 0.07     

  LMEDn, nm                                                   27.03 ± 0.78                 0.59 ± 0.07     

  LDLppd, nm                                                  27.35 ± 1.2                  0.65 ± 0.07     

  BMED, nm                                                    27.55 ± 1.17                 0.63 ± 0.07     

  Systolic Blood Pressure (sBP), mmHg                         124.58 ± 18.57               0.24 ± 0.05     

  Diastolic Blood Pressure (dBP), mmHg                        77.13 ± 11.27                0.24 ± 0.06     

  Pulse, beats/min                                            71.17 ± 14.14                0.20 ± 0.05     

                                                                                                           

  **Adipokine**\                                              Adiponectin, ng/ml           9.51 ± 5.6      0.48 ± 0.06
  **and**\                                                                                                 
  **cytokines**                                                                                            

  Leptin, ng/ml                                               19.28 ± 17.3                 0.24 ± 0.06     

  TNF-alpha, pg/ml                                            4.44 ± 6.28                  0.32 ± 0.06     

  Interleukin-1 beta (IL-1β), pg/ml                           1.33 ± 18.42                 0.16 ± 0.06     

  Interleukin-6 (IL-6), pg/ml                                 7.68 ± 53.48                 0.25 ± 0.07     
  ----------------------------------------------------------------------------------------------------------------------------

###### MetS SNP association with phenotypes and their gene annotation at 3q27 QTL

SNPs within 1 LOD reduction from the linkage peak were tested against the 42 phenotypes. For phenotypic abbreviations, see [Table 1](#T1){ref-type="table"}. SNPs were mapped to genes and the known functions of these genes summarized, based on data from the NCBI build 36 human genome assembly. Annotations were determined at the position and within 250kb up- and downstream of the associated SNP. Data shown in column "−Log10(p)" are levels of the highest association. The QTL-specific significance threshold based on the effective number of SNPs was p~0.05~=1.32×10^−5^, −log(p-value)=4.941. Prioritized biologically relevant genes are shaded in gray and SNP associations that exceed statistical QTL-specific significance threshold are bolded. MAF, minor allele frequency.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    Variant      Minor\   MAF    −Log10(p)      Associated\     Nearest gene   Location                       Annotation
                                                                 Allele                         phenotype                                                     
  ------------------------------------------------- ------------ -------- ------ -------------- --------------- -------------- ------------------------------ ---------------------
  **Body composition and insulin responsiveness**   rs6443434    A        0.43   3.76           Weight          TBL1XR1        upstream                       signal transduction

  rs11710431                                        A            0.19     4.55   Height         TBL1XR1         intergenic     signal transduction            

  rs6443434                                         A            0.43     3.49   BMI            TBL1XR1         upstream       signal transduction            

  rs6772734                                         A            0.02     3.82   WC             LOC131583       intergenic     unknown function               

  rs13068101                                        T            0.28     3.06   HC             C3orf59         intergenic     unknown function               

  rs12639517                                        T            0.33     4.03   WHR            IGF2BP2         intergenic     controls IGF translation       

  rs11708240                                        G            0.14     3.54   Fatkg          NAALADL2        intergenic     dipeptidase                    

  rs13098487                                        G            0.22     3.59   Fatpct         NLGN1           intronic       brain synapses                 

  rs569221                                          A            0.19     4.47   Leankg         NLGN1           intronic       brain synapses                 

  rs301177                                          C            0.23     3.39   Leanpct        TBL1XR1         intergenic     signal transduction            

  rs4074869                                         C            0.44     3.70   SubQF          EPHB3           intergenic     ephrinB receptor               

  rs7433602                                         T            0.29     5.03   VF             NAALADL2        intronic       dipeptidase                    

  rs12496403                                        A            0.01     3.76   TAF            TBL1XR1         intergenic     signal transduction            

  rs13324849                                        T            0.09     4.39   RQ             NAALADL2        intergenic     dipeptidase                    

  rs6443434                                         A            0.43     3.51   REE            TBL1XR1         upstream       signal transduction            

  rs4074869                                         C            0.44     4.47   REE/weight     EPHB3           intergenic     ephrinB receptor               

  rs13321995                                        A            0.40     4.89   REE/Leanmass   C3orf21         intronic       unknown function               

  rs6807927                                         A            0.27     3.96   FG             SENP2           intronic       SUMO protease                  

  rs10933727                                        G            0.32     4.43   FI             LOC100131551    intergenic     unknown function               

  rs2513                                            A            0.10     3.57   IGR            AK091265        downstream     unknown function               

  rs10933727                                        G            0.32     5.93   HOMA           LOC100131551    intergenic     unknown function               

  rs9814412                                         T            0.27     3.90   SI             HRG             5'UTR          thrombosis                     

  rs1463332                                         C            0.32     3.29   SG             TBL1XR1         intergenic     signal transduction            

  rs6785028                                         T            0.26     3.87   AIR            LPP             intronic       cell adhesion                  

  rs937589                                          T            0.02     3.70   DI             C3orf59         intronic       unknown function               

                                                                                                                                                              

  **Lipids/lipoprotein profiles**\                  rs10804867   A        0.26   3.74           TG              TBL1XR1        intergenic                     signal transduction
  **and cardiovascular**\                                                                                                                                     
  **performance**                                                                                                                                             

  rs1895070                                         A            0.10     4.66   TC             mRNA FLJ31690   downstream     unknown function               

  rs1895070                                         A            0.10     4.25   LDL-c          mRNA FLJ31690   downstream     unknown function               

  rs1895070                                         A            0.10     4.57   cal.LDL-c      mRNA FLJ31690   downstream     unknown function               

  rs4452373                                         G            0.00     3.90   HDL-c          mRNA HQ448050   intergenic     unknown function               

  rs9716                                            C            0.24     3.55   HMED           ST6GAL1         downstream     glycosyltransferase            

  rs6793161                                         T            0.01     3.62   LMEDn          mRNA AF338197   intergenic     unknown function               

  rs2700839                                         C            0.12     3.70   LDLppd         ATP11B          intergenic     ATPase                         

  rs10937009                                        G            0.00     5.14   BMED           NDUFB5          intergenic     repiratory chain               

  rs260589                                          G            0.33     3.27   sBP            TPRG1           intergenic     tumor protein regulated        

  rs6444517                                         G            0.10     4.64   dBP            OSTN            intergenic     osteoblastic differentiation   

  rs7631640                                         C            0.09     4.51   Pulse          MCF2L2          downstream     guanine exchange factor        

                                                                                                                                                              

  **Adipokine**\                                    rs17427594   C        0.10   3.60           Adiponectin     CLDN1          intergenic                     cell junction
  **and**\                                                                                                                                                    
  **cytokines**                                                                                                                                               

  rs6772734                                         A            0.02     3.45   Leptin         FAM43A          intergenic     unknown function               

  rs13070418                                        T            0.36     5.06   TNFalfa        SOX2            intergenic     transcription factor           

  rs9877500                                         C            0.22     4.11   IL-1β          IQCG            intronic       unknown function               

  rs6807480                                         A            0.36     3.60   IL-6           FGF12           intronic       fibroblast growth factor       
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### MetS SNP association with phenotypes and their gene annotation at 17p12 QTL

SNPs within 1 LOD reduction from the linkage peak were tested against the 42 phenotypes. For phenotypic abbreviations, see [Table 1](#T1){ref-type="table"}. SNPs were mapped to genes and the known functions of these genes summarized, based on data from the NCBI build 36 human genome assembly. Annotations were determined at the position and within 250kb up- and downstream of the associated SNP. Data shown in column "−Log10(p)" are levels of the highest association. The QTL-specific significance threshold based on the effective number of SNPs was ρ~α=0.05~=3.63×10^−5^, −log(p-value)=4.361. Prioritized biologically relevant genes are shaded in gray and SNP associations that exceed statistical QTL-specific significance threshold are bolded. MAF, minor allele frequency.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    Variant     Minor\   MAF        −Log10(p)      Associated\    Nearest gene   Location              Annotation
                                                                Allele                             phenotype                                           
  ------------------------------------------------- ----------- -------- ---------- -------------- -------------- -------------- --------------------- ------------------
  **Body composition and insulin responsiveness**   rs9889434   T        0.46       2.56           Weight         MYOCD          intergenic            Cardiogenesis

  rs12943502                                        C           0.49     3.15       Height         NM_001001684   intergenic     unknown function      

  rs2052003                                         T           0.33     2.77       BMI            MYOCD          intronic       Cardiogenesis         

  rs2052003                                         T           0.33     2.99       WC             MYOCD          intronic       Cardiogenesis         

  rs4792371                                         G           0.46     3.35       HC             HS3ST3A1       intronic       heparan sulfate       

  rs7219760                                         T           0.09     2.96       WHR            NM_001001684   intergenic     unknown function      

  rs9893022                                         A           0.03     2.75       Fatkg          HS3ST3A1       intergenic     heparan sulfate       

  rs2190699                                         G           0.34     2.95       Fatpct         RICH2          intronic       GTPase activator      

  rs3944086                                         C           0.11     2.80       Leankg         HS3ST3A1       intergenic     heparan sulfate       

  rs9907078                                         C           0.33     3.02       Leanpct        CDRT15         upstream       unknown function      

  rs12949155                                        G           0.43     3.47       SubQF          NM_001001684   intergenic     unknown function      

  rs4343329                                         C           0.26     **6.54**   VF             TNFRSF13B      intronic       pro-inflammation      

  rs7225344                                         C           0.26     **5.68**   VF             TNFRSF13B      intronic       pro-inflammation      

  rs4985700                                         C           0.40     **5.13**   VF             TNFRSF13B      intronic       pro-inflammation      

  rs7226097                                         C           0.41     4.22       VF             TNFRSF13B      intronic       pro-inflammation      

  rs11651352                                        A           0.23     4.17       VF             TNFRSF13B      downstream     pro-inflammation      

  rs4343329                                         C           0.26     **5.23**   TAF            TNFRSF13B      intronic       pro-inflammation      

  rs8081054                                         A           0.33     **4.74**   TAF            NM_001001684   intergenic     unknown function      

  rs7225344                                         C           0.26     **4.51**   TAF            TNFRSF13B      intronic       pro-inflammation      

  rs8079010                                         A           0.34     3.98       RQ             TRPV2          intronic       stress response       

  rs4985700                                         C           0.40     4.01       REE            TNFRSF13B      intronic       pro-inflammation      

  rs9303119                                         G           0.45     2.81       REE/weight     NM_001001684   intergenic     unknown function      

  rs7222088                                         G           0.43     3.53       REE/Leanmass   AK123100       intronic       unknown function      

  rs2108683                                         A           0.11     3.48       FG             COX10          intronic       Respiratory chain     

  rs3744342                                         G           0.48     3.04       FI             HS3ST3A1       intergenic     heparan sulfate       

  rs3744342                                         G           0.48     2.91       IGR            HS3ST3A1       intergenic     heparan sulfate       

  rs6502302                                         A           0.01     2.87       HOMA           HS3ST3A1       intergenic     heparan sulfate       

  rs9908356                                         G           0.21     3.19       SI             PMP22          intergenic     Peripheral nervous    

  rs2106795                                         T           0.14     3.79       SG             HS3ST3A1       intergenic     heparan sulfate       

  rs2996033                                         T           0.25     2.95       AIR            HS3ST3A1       intergenic     heparan sulfate       

  rs12453295                                        A           0.01     3.02       DI             MYOCD          intronic       Cardiogenesis         

                                                                                                                                                       

  **Lipids/lipoprotein and**\                       rs4792303   A        0.05       2.80           TG             RICH2          intronic              GTPase activator
  **cardiovascular performance**                                                                                                                       

  rs173160                                          C           0.34     3.22       TC             MYOCD          intergenic     Cardiogenesis         

  rs11870163                                        T           0.42     3.11       LDL-c          HS3ST3B1       intronic       heparan sulfate       

  rs173160                                          C           0.34     2.72       cal. LDL-c     MYOCD          intergenic     Cardiogenesis         

  rs8077611                                         A           0.01     3.54       HDL-c          NM_001001684   intergenic     unknown function      

  rs230922                                          T           0.30     5.21       HMED           PMP22          intergenic     Peripheral nervous    

  rs7214429                                         G           0.45     3.64       LMEDn          MPRIP          intronic       Myosin phosphatase    

  rs7214429                                         G           0.45     3.20       LDLppd         MPRIP          intronic       Myosin phosphatase    

  rs7214429                                         G           0.45     3.58       bMED           MPRIP          intronic       Myosin phosphatase    

  rs7214091                                         C           0.40     4.05       sBP            TNFRSF13B      intergenic     heparan sulfate       

  rs1233861                                         A           0.23     3.36       dBP            MYOCD          intergenic     Cardiogenesis         

  rs12944789                                        C           0.36     **4.36**   Pulse          NM_001001684   intergenic     unknown function      

                                                                                                                                                       

  **Adipokine**\                                    rs8070118   G        0.41       2.22           Adiponectin    HS3ST3A1       intergenic            heparan sulfate
  **and**\                                                                                                                                             
  **cytokines**                                                                                                                                        

  rs2906985                                         G           0.06     3.75       Leptin         CDRT4          intronic       unknown function      

  rs9915627                                         A           0.21     4.13       TNF-alpha      HS3ST3A1       intergenic     heparan sulfate       

  rs9904641                                         T           0.27     3.48       IL-1β          CDRT4          downstream     unknown function      

  rs1736202                                         C           0.41     3.60       IL-6           COPS3          intronic       signal transduction   
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### Association of lymphocyte expression levels of prioritized genes with MetS phenotypes at 3q27 QTL

For gene prioritization strategy, see text. SNP associations with phenotypes are depicted in [Table 2](#T2){ref-type="table"}. The values shown represent the level of significance (p-value) of association between prioritized gene transcript levels and MetS phenotypes.

  ----------------------------------------------------------------------------------------------------------------------------
                                                    Phenotype     ATP11B   FGF12   IGF2BP2   LPP    MCF2L2   NLGN1   TBL1XR1
  ------------------------------------------------- ------------- -------- ------- --------- ------ -------- ------- ---------
  **Body composition and insulin responsiveness**   weight        0.51     0.35    0.00      0.62   0.96     0.18    1.00

  height                                            0.17          0.14     0.12    0.97      1.00   0.31     0.00    

  BMI                                               1.00          0.89     0.00    0.74      0.36   0.21     0.34    

  WC                                                0.44          0.63     0.00    0.69      0.73   0.68     0.34    

  HC                                                0.01          0.57     0.01    0.50      0.63   0.80     0.28    

  WHR                                               0.02          0.39     0.12    0.37      0.51   0.92     0.69    

  Fatkg                                             0.61          0.73     0.02    0.34      0.84   0.16     0.09    

  Fatpct                                            0.93          0.96     0.27    0.48      0.18   0.18     0.65    

  Leankg                                            0.14          0.70     0.00    0.86      0.33   0.10     0.01    

  Leanpct                                           0.93          1.00     0.26    0.43      0.25   0.16     0.55    

  SubQF                                             0.82          0.28     0.06    0.74      0.84   NA       0.96    

  VF                                                0.81          0.28     0.21    0.91      0.83   NA       0.89    

  TAF                                               0.86          0.24     0.11    0.80      0.94   NA       0.86    

  RQ                                                0.18          0.90     0.01    0.22      0.06   NA       0.84    

  REE                                               0.81          0.63     0.00    0.20      0.45   NA       0.52    

  REE/weight                                        0.24          0.99     0.09    0.03      0.12   NA       0.29    

  REE/leanmass                                      0.43          0.86     0.38    0.08      0.93   NA       0.31    

  FG                                                0.57          0.77     0.21    0.71      0.74   0.04     0.83    

  FI                                                0.73          0.12     0.68    0.05      0.81   0.85     0.13    

  IGR                                               0.55          0.20     0.68    0.05      0.99   0.58     0.13    

  HOMA                                              0.79          0.15     0.40    0.06      0.67   0.41     0.16    

  SI                                                0.07          0.13     0.04    0.67      0.04   NA       0.64    

  SG                                                0.83          0.51     0.17    0.75      0.37   NA       0.62    

  AIR                                               0.19          0.15     0.45    0.94      0.98   NA       0.31    

  DI                                                0.18          0.26     0.02    0.49      0.83   0.57     0.73    

                                                                                                                     

  **Lipids/lipoprotein profiles and**\              TG            0.46     0.35    0.90      0.01   0.30     0.44    0.62
  **cardiovascular performance**                                                                                     

  TC                                                0.64          0.91     0.12    0.94      0.77   0.45     0.84    

  LDL-c                                             0.45          0.68     0.02    0.60      0.35   0.86     0.17    

  cal. LDL-c                                        0.50          0.58     0.76    0.67      0.62   0.75     0.95    

  HDL-c                                             0.20          0.35     0.08    0.02      0.64   0.15     0.67    

  HMED                                              0.81          0.97     0.02    0.49      0.60   0.08     0.56    

  LMEDn                                             0.81          0.93     0.10    0.67      0.44   0.46     0.76    

  LDLppd                                            0.56          0.58     0.03    0.89      0.01   0.31     0.35    

  BMED                                              0.88          0.50     0.19    0.90      0.04   0.86     0.65    

  sBP                                               0.40          0.51     0.07    0.79      0.45   0.45     0.83    

  dBP                                               0.79          0.25     0.71    0.62      0.37   0.49     0.67    

  Pulse                                             0.67          0.70     0.56    0.36      0.23   0.30     0.00    

                                                                                                                     

  **Adipokine**\                                    Adiponectin   0.22     0.30    0.05      0.37   0.92     0.57    0.84
  **and**\                                                                                                           
  **cytokines**                                                                                                      

  Lepin                                             0.76          0.61     0.05    0.73      0.10   0.77     0.40    

  TNF-alpha                                         0.90          0.81     0.94    0.32      0.95   0.45     0.63    

  IL-1β                                             0.58          0.59     0.59    0.04      1.00   0.57     0.81    

  IL-6                                              0.34          0.87     0.57    0.82      0.42   0.84     0.79    
  ----------------------------------------------------------------------------------------------------------------------------

###### Association of lymphocyte expression levels of prioritized genes with MetS phenotypes at 17p12 QTL

For gene prioritization strategy, see text. SNP associations with phenotypes are depicted in [Table 3](#T3){ref-type="table"}. The values shown represent the level of significance (p-value) of association between prioritized gene transcript levels and MetS phenotypes.

  ------------------------------------------------------------------------------------------------------------------------------
                                                    Phenotype     COPS3   COX10   PMP22   RICH2   TNFRSF13B   TRPV2   HS3ST3B1
  ------------------------------------------------- ------------- ------- ------- ------- ------- ----------- ------- ----------
  **Body composition and insulin responsiveness**   weight        0.30    0.04    0.58    0.26    0.43        0.92    0.58

  height                                            0.85          0.18    0.73    0.57    0.86    0.67        0.21    

  BMI                                               0.19          0.01    0.71    0.41    0.24    0.95        0.26    

  WC                                                0.67          0.23    0.46    0.45    0.64    0.94        0.76    

  HC                                                0.59          0.09    0.14    0.35    0.24    1.00        0.41    

  WHR                                               0.66          0.13    0.54    0.95    0.03    0.37        0.26    

  Fatkg                                             0.99          0.22    0.41    0.14    0.65    0.03        0.46    

  Fatpct                                            0.93          0.16    0.62    0.19    0.36    0.03        0.19    

  Leankg                                            1.00          0.23    0.61    0.03    0.58    0.81        0.49    

  Leanpct                                           0.89          0.17    0.53    0.17    0.46    0.03        0.19    

  SubQF                                             0.55          0.23    0.67    0.39    0.23    0.04        NA      

  VF                                                0.88          0.40    0.59    0.44    0.58    0.80        NA      

  TAF                                               0.75          0.24    0.65    0.49    0.24    0.10        NA      

  RQ                                                0.83          0.20    0.84    0.16    0.01    0.39        NA      

  REE                                               0.45          0.94    0.59    0.02    0.94    0.75        NA      

  REE/weight                                        0.85          0.97    0.99    0.00    0.83    0.99        NA      

  REE/leanmass                                      0.07          1.00    0.93    0.16    0.94    0.00        NA      

  FG                                                0.33          0.17    1.00    0.64    0.11    0.39        0.66    

  FI                                                0.68          0.07    0.07    0.64    0.14    0.53        0.81    

  IGR                                               0.26          0.20    0.15    0.34    0.20    0.58        0.95    

  HOMA                                              0.90          0.06    0.15    0.81    0.23    0.48        0.73    

  SI                                                0.41          0.81    0.84    0.05    0.12    0.16        NA      

  SG                                                0.10          0.05    0.88    0.62    0.13    0.49        NA      

  AIR                                               0.28          0.38    0.65    0.03    0.60    0.42        NA      

  DI                                                1.00          0.59    0.54    0.07    0.34    0.35        0.34    

                                                                                                                      

  **Lipids/lipoprotein profiles and**\              TG            0.70    0.04    0.01    0.79    0.91        0.19    0.47
  **cardiovascular performance**                                                                                      

  TC                                                0.91          0.63    0.68    0.69    0.21    0.40        0.90    

  LDL-c                                             0.83          0.28    0.32    0.27    0.75    0.45        0.99    

  cal. LDL-c                                        0.99          0.91    0.26    0.45    0.26    0.40        0.84    

  HDL-c                                             0.31          0.46    0.42    0.19    0.26    0.29        0.97    

  HMED                                              0.26          0.22    0.04    0.78    0.03    0.19        0.21    

  LMEDn                                             0.71          0.55    0.16    0.82    0.06    0.63        0.28    

  LDLppd                                            0.74          0.81    0.03    0.08    0.00    0.15        0.90    

  BMED                                              0.96          0.95    0.46    0.27    0.00    0.34        0.43    

  sBP                                               0.96          0.47    0.54    0.41    0.20    0.30        0.89    

  dBP                                               0.54          0.89    0.09    0.95    0.33    0.22        0.43    

  pulse                                             0.50          0.94    0.36    0.81    0.34    0.07        0.33    

                                                                                                                      

  **Adipokine**\                                    adiponectin   0.95    0.76    0.77    0.47    0.29        0.45    0.34
  **and**\                                                                                                            
  **cytokines**                                                                                                       

  leptin                                            0.55          0.69    0.45    0.05    0.08    0.99        0.14    

  TNF-alpha                                         0.02          0.17    0.70    0.60    0.81    0.46        0.21    

  IL-1β                                             0.39          0.53    0.21    0.48    0.40    0.53        0.40    

  IL-6                                              0.66          0.76    0.31    0.05    0.55    0.34        0.36    
  ------------------------------------------------------------------------------------------------------------------------------

###### Summary illustrating the prioritized genes at 3q27 and 17p12 QTLs

For prioritized genes see [Table 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}. For phenotype abbreviations, see [Table 1](#T1){ref-type="table"}. Identifier phenotype is the one that was highly associated with a SNP that mapped to that gene. Correlated phenotypes are those that were found to be genetically correlated significantly with the identifier phenotype.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Annotated\                                                               Original\   Identifier\     Correlated biological\                 Biological function
  associated\                                                              QTL\        phenotype       phenotypes                             
  genes                                                                    region                                                             
  ------------------------------------------------------------------------ ----------- --------------- -------------------------------------- ----------------------------------------------------
  LPP[a](#TFN1){ref-type="table-fn"}[b](#TFN2){ref-type="table-fn"}        3q27        AIR             Fatkg, DI, leptin                      signal transduction to celll adhesion sites; cell\
                                                                                                                                              to cell communication

  IGF2BP2[a](#TFN1){ref-type="table-fn"}[b](#TFN2){ref-type="table-fn"}    3q27        WHR             VF, TAF, REE, HMED, LMEDn,\            neonatal development, body fat regulation\
                                                                                                       LDLppd, BMED,TNF-alpha                 and lipid metabolism

  TBL1XR1[a](#TFN1){ref-type="table-fn"}                                   3q27        BMI, weight,\   WHR, Fatkg, Fatpct, Leankg,\           member of WD40 protein family known to\
                                                                                       Leanpct,\       Leanpct, SubQF, VF,\                   regulate signal transduction, RNA processing,\
                                                                                       TAF,\           REE/weight, REE/Leanmass,\             vesicular trafficking, cytoskeletal assembly\
                                                                                       REE,SG, TG      SI, AIR, DI, HMED, leptin, IL-6        and\
                                                                                                                                              cytotypic differentiation.

  NLGN1[a](#TFN1){ref-type="table-fn"}                                     3q27        Leankg          Fatkg, SubQF, VF, TAF, REE,\           member of a family of neuronal cell surface\
                                                                                                       REE/weight, REE/leanmass, SI,\         proteins, known to act as splice\
                                                                                                       AIR, HMED                              site-specific ligands for beta-neurexins that\
                                                                                                                                              could be involved in the formation and\
                                                                                                                                              remodeling of central nervous system

  ATP11B[a](#TFN1){ref-type="table-fn"}                                    3q27        LDLppd          WHR, Fatkg, HMED,BMED,TNF-\            member of the ATPase family that participate\
                                                                                                       alpha                                  the uphill transport of ions across cell\
                                                                                                                                              membranes, including H+,Na+, K+ and Ca++

  MCF2L2[a](#TFN1){ref-type="table-fn"}                                    3q27        Pulse           Leankg, SubQF, TAF, REE, SI,\          member of the guanine exchange factor\
                                                                                                       adiponectin, leptiin                   family. Together with ADIPQ, SOX2\
                                                                                                                                              polymorphism influence diabetic\
                                                                                                                                              complications.

  FGF12                                                                    3q27        IL-6            VF                                     Member of the fibroblast growth factor family\
                                                                                                                                              possess\
                                                                                                                                              broad mitogenic and cell survival\
                                                                                                                                              activities,involved in several biological\
                                                                                                                                              functions.

  TNFRSF13B\                                                               17p12       VF, TAF,\       weight, BMI, WC, HC,\                  A lymphocyte-specific member of the\
  [a](#TFN1){ref-type="table-fn"}[b](#TFN2){ref-type="table-fn"}                       REE, sBP        WHR,Fatkg,Fatpct,Leankg,Leanpc\        tumor necrosis factor (TNF) receptor\
                                                                                                       t,SubQF,REE/weight, FI, IGR,,\         superfamily, which plays a crutial role in\
                                                                                                       HOMA, SI,SG,DI, HDL-c,\                humoral immunity.
                                                                                                       dBP,pulse, leptin, IL-6                

  HS3ST3A1[a](#TFN1){ref-type="table-fn"}[b](#TFN2){ref-type="table-fn"}   17p12       HC, Fatkg,\     weight, height,, BMI, WC,\             A biosynthesis enzyme of heparan\
                                                                                       Leankg, FI,\    WHR,SubQF,VF, TAF,RQ, REE,\            sulfate find structures, whose substrates\
                                                                                       IGR, HOMA,\     REE/weight, REE/leanmass, FG,\         are important in the cellular uptake and\
                                                                                       SG, AIR,\       SI, DI,TG,TC, LDL-c, cal. LDL-c,\      biological effects of the lipoproteins that\
                                                                                       Adiponectin,\   HDL-c, HMED, LMEDn, LDLppd,\           carry out multiple biologic activities.
                                                                                       TNF-alpha       BMED, sBP,pulse, leptin, IL-1β, IL-\   
                                                                                                       6                                      

  MYOCD[a](#TFN1){ref-type="table-fn"}                                     17p12       Weight,\        height, hips,WHR, Fatkg, Fatpct,\      A nuclear protein, a transcriptional coactivator\
                                                                                       BMI, WC,\       Leankg, Leanpct, SubQF,\               that modulates the function of\
                                                                                       DI, TC, cal.\   VF,TAF,REE, REE/weight,\               cardiac and smooth-muschle cells.\
                                                                                       LDL-c, dBP      REE/leanmass, FI, IGR, HOMA,\          Important in cardiogenesis and smooth\
                                                                                                       SI,SG, AIR,TG, LDL-c, HDL-c,\          muscle cell differentiation.
                                                                                                       HMED, sBP, pulse, leptin, IL-6         

  RICH2[a](#TFN1){ref-type="table-fn"}                                     17p12       Fatpct, TG      weight, BMI, WC,HC,WHR,\               GTPase activator protein, which activate\
                                                                                                       Fatkg,Leanpct, SubQF, VF, TAF,\        CDC42 and Rac-1, known to interfere\
                                                                                                       REE,\                                  with platelet growth factor BB-induced\
                                                                                                       REE/weight,REE/leanmass,FI,\           membrane ruffling.
                                                                                                       IGR, HOMA, SI,AIR,TC,HDL-c,\           
                                                                                                       leptin                                 

  TRPV2[a](#TFN1){ref-type="table-fn"}                                     17p12       RQ              Pulse                                  A channel protein in response to\
                                                                                                                                              environmental stresses.

  COX10[a](#TFN1){ref-type="table-fn"}                                     17p12       FG              FI, HOMA, AIR, leptin                  The terminal component of the\
                                                                                                                                              mitochodrial respiratory chain, which\
                                                                                                                                              catalyzes the electron\
                                                                                                                                              transfer from reduced cytochrome c to\
                                                                                                                                              oxygen. Mutations were linked to\
                                                                                                                                              cytochrome c function deficiency.

  PMP22[a](#TFN1){ref-type="table-fn"}                                     17p12       SI, HMED        weight, BMI, WC, HC, WHR,\             the major component of the myelin\
                                                                                                       Fatkg, Fatpct,Leankg,\                 structure in the peripheral nervous\
                                                                                                       Leanpct,SubQF, VF, TAF,\               system that might function in growth\
                                                                                                       REE/weight, FI, IGR, HOMA, TG,\        regulation, and in myelinization in the\
                                                                                                       HDL-c, LMEDn, LDLppd,\                 peripheral nervous system
                                                                                                       BMED,pulse                             

  MPRIP[a](#TFN1){ref-type="table-fn"}                                     17p12       LMEDn,\         WHR,Fatkg, FI, IGR, HOMA, TG,\         Target myosin phosphatases interacting\
                                                                                       LDLppd,\        HDL-c, HMED,TNF-alpha                  with RhoA and ROCK1 to regulate actin\
                                                                                       BMED                                                   cytoskeleton.

  COPS3                                                                    17p12       IL-6            BMI, VF                                The protein encoded by this gene\
                                                                                                                                              possesses kinase activity that\
                                                                                                                                              phosphorylates regulators involved in\
                                                                                                                                              signal transduction and protects proteins\
                                                                                                                                              from ubiquitin-dependent degradation.
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